Leadership
The MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, created in 2008, was inspired by the late Dr. John Mendelsohn’s vision to offer individualized therapies for cancer patients.
The establishment of a streamlined pipeline for comprehensive biospecimen profiling and data analytics, access and integration led to the expansion of the Khalifa Institute to support this integrated pipeline for comprehensive profiling. The institute's leadership structure reflects and supports this expansion.
This approach will allow MD Anderson to simplify and enrich the development and implementation of translational research for all our research investigators and enhance our access to and deep understanding of the resulting genomic, proteomic and immune data.
Andrew Futreal, Ph.D., Scientific Director
Funda Meric-Bernstam, M.D., Medical Director
Ignacio Wistuba, M.D., Translational Research Director
Kenna Shaw, Ph.D., Executive Director